Filing Details

Accession Number:
0000899243-15-004077
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2015-08-26 18:56:29
Reporting Period:
2015-08-21
Filing Date:
2015-08-26
Accepted Time:
2015-08-26 18:56:29
Original Submission Date:
2015-08-24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1014739 Bioscrip Inc. BIOS Retail-Drug Stores And Proprietary Stores (5912) 050489664
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1356974 P L Partners Capital Coliseum Metro Center
1 Station Place, 7Th Floor,
Stamford CT 06902
Yes No Yes No
1409585 Coliseum Capital, Llc Metro Center
1 Station Place, 7Th Floor,
Stamford CT 06902
Yes No Yes No
1409751 Coliseum Capital Management, Llc Metro Center
1 Station Place, 7Th Floor South
Stamford CT 06902
Yes No Yes No
1430708 S Christopher Shackelton Metro Center
1 Station Place, 7Th Floor,
Stamford CT 06902
Yes No Yes No
1454123 Adam Gray Metro Center
1 Station Place, 7Th Floor,
Stamford CT 06902
Yes No Yes No
1567187 Coliseum Capital Partners Ii, L.p. Metro Center
1 Station Place, 7Th Floor,
Stamford CT 06902
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-08-21 397,900 $1.82 632,907 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. These securities are held directly by (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2" and, together with CCP, the "Funds"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, and (c) a separate account investment advisory client of CCM (the "Separate Account").
  3. Christopher Shackelton ("Shackelton") and Adam Gray ("Gray") are managers of and have an ownership interest in each of CCM and CC and may be deemed to have an indirect pecuniary interest in the shares held by the Funds and the Separate Account due to CCM's right to receive performance-related fees from the Separate Account and CC's right to receive performance-related fees from the Funds. Each of Shackelton, Gray, CCP, CCP2, the Separate Account, CC and CCM disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.
  4. Following the transactions reported herein, CCP, CCP2 and the Separate Account directly owned 380,186, 98,739 and 153,982 shares of common stock, respectively.
  5. The transaction is not new, but is being reported again to gain access to the system. The amount of shares of common stock directly owned by CCP, CCP2 and the Separate Account following the transactions reported on August 24, 2015 was originally reported as 380,186, 119,364 and 133,357 shares, respectively. This amendment to Form 4 reflects the correct amount of shares of common stock directly owned by CCP, CCP2 and the Separate Account following the transactions reported on August 24, 2015 as 380,186, 98,739 and 153,982 shares, respectively.